Researchers with Biodesix and Genentech presented findings on a test designed to predict response to atezolizumab (Tecentriq) in patients with non-small cell lung cancer.
The blood-based test, which uses expression data from the circulating proteome to classify patients, was found to be predictive for OS and PFS between atezolizumab and docetaxel, the companies said.
Genentech is a member of the Roche Group.
These data suggest a patient’s likelihood of benefiting from PD-L1 checkpoint inhibition can be identified through circulating proteome in blood samples. Researchers presented their findings at the Society for Immunotherapy of Cancer annual meeting in Washington, D.C.
Biodesix test predicts response to atezolizumab in lung cancer
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
THE CLINICAL CANCER LETTER
YOU MAY BE INTERESTED IN
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
![](https://cdn.cancerletter.com/media/2024/07/12143220/Rejeski-and-Shouval-4x31-1.jpg)
![](https://cdn.cancerletter.com/media/2024/07/12143220/Rejeski-and-Shouval-4x31-1.jpg)
Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.
![](https://cdn.cancerletter.com/media/2024/07/12143216/Erickson-4x3-1.jpg)
![](https://cdn.cancerletter.com/media/2024/07/12143216/Erickson-4x3-1.jpg)
Two decades after uncovering the role of EGFR mutations in lung cancer, scientists are still grappling with lingering research questions.
![](https://cdn.cancerletter.com/media/2024/07/12143212/Archives-4x3-1.jpg)
![](https://cdn.cancerletter.com/media/2024/07/12143212/Archives-4x3-1.jpg)
Lei Zheng was named executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and vice president for oncology for the University of Texas Health Science Center at San Antonio.
Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.